

## **Zydus receives tentative approval from the USFDA for Mesalamine Suppositories for rectal use**

---

*Ahmedabad, 11 August 2017*

Zydus Cadila has received the tentative approval from the USFDA to market Mesalamine Suppositories for rectal use, 1000 mg. Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical plant at Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*